Groupe d'Etude en Oncologie du Quebec

Titre	Personalized Peptide Receptor Radionuclide Therapy of Neuroendocrine Tumors: A Phase 2 Study
Protocole ID	A14-11-2181
ClinicalTrials.gov ID	NCT02754297
Type(s) de cancer	Tumeurs neuroendocrines
Phase	Phase II
Institution	CHU DE QUEBEC – UNIVERSITE LAVAL L'HOTEL-DIEU DE QUEBEC ET CRCEO 11 Côte du Palais, Québec, QC, G1R 2J6
Ville	Québec
Investigateur(trice) principal(e)	Dr Jean-Mathieu Beauregard
Coordonnateur(trice)	Guillaume Bouvet 418-525-4444
Statut	Actif en recrutement
Critètes d'éligibilité	Patient suffering from a progressive and/or symptomatic NET (any site); Patient ineligible to, or refusing a potentially curative treatment such as surgical resection; Patient who did not respond, is intolerant or refuses other indicated and available palliative treatments; Demonstration of overexpression of somatostatin receptor by tumor lesions by scintigraphic imaging (Octreoscan or 68Ga positron emission tomography.
Critètes d'exclusion	Pregnancy; Breastfeeding;. Very limited survival prognosis (i.e. less than a few weeks, because of the NET disease or any other condition) or Eastern Cooperative Oncology Group (ECOG) 4 performance status; Inability to obtain informed consent of the participant.

Groupe d'étude en oncologie du Québec